Results 21 to 30 of about 15,728 (206)

Efficacy and Safety of Dual Antiplatelet Therapy with the Routine Use of Prasugrel for Flow Diversion of Cerebral Unruptured Aneurysms

Clinical Neuroradiology, 2023
Purpose Prasugrel is not approved for patients treated with flow diverters, which have a high metal coverage ratio. However, robust antiplatelet therapy with prasugrel may prevent thromboembolic complications. We administered prasugrel and aspirin to all
Kenichiro Suyama, Ichiro Nakahara, Shoji Matsumoto, Junichiro Morioka, Jun Tanabe, Akiko Hasebe, Sadayoshi Watanabe   +6 more
semanticscholar   +1 more source

Reduced-dose prasugrel monotherapy without aspirin after PCI with the SYNERGY stent in East Asian patients presenting with chronic coronary syndromes or non-ST-elevation acute coronary syndromes: rationale and design of the ASET Japan pilot study.

AsiaIntervention, 2023
The Acetyl Salicylic Elimination Trial (ASET) Japan pilot study is a multicentre, single-arm, open-label, proof-of-concept study with a stopping rule based on the occurrence of definite stent thrombosis. This study aims to demonstrate the feasibility and
S. Masuda, T. Muramatsu, Y. Ishibashi, K. Kozuma, K. Tanabe, Shimpei Nakatani, Norihiro Kogame, M. Nakamura, T. Asano, T. Okamura, Yosuke Miyazaki, Hiroki Tateishi, Y. Ozaki, G. Nakazawa, Y. Morino, Y. Katagiri, S. Garg, H. Hara, M. Ono, Hideyuki Kawashima, P. Lemos, P. Serruys, Y. Onuma   +22 more
semanticscholar   +1 more source

Comparison of Prasugrel and Clopidogrel in Thrombotic Stroke Patients with Risk Factors for Ischemic Stroke Recurrence: An Integrated Analysis of PRASTRO-I, PRASTRO-II, and PRASTRO-III

Cerebrovascular Diseases, 2023
Introduction: Patients with stroke are at a high risk of recurrence, and although they receive antiplatelet therapies such as clopidogrel for secondary prevention of non-cardioembolic stroke, the recurrence rate remains high.
T. Kitazono, M. Kamouchi, Y. Matsumaru, Toshiaki Shirai, A. Takita, Takeshi Kuroda, K. Kimura   +6 more
semanticscholar   +1 more source

Effects of concomitant use of prasugrel with edoxaban on bleeding time, pharmacodynamics, and pharmacokinetics of edoxaban in healthy elderly Japanese male subjects: a clinical pharmacology study

Thrombosis Journal, 2020
Background Dual therapy with a direct oral anticoagulant (DOAC) plus a P2Y12 receptor inhibitor is recommended in patients with nonvalvular atrial fibrillation who undergo percutaneous coronary intervention.
Ippei Ikushima, Takaaki Akasaka, Yoshiyuki Morishima, Atsushi Takita, Tomoko Motohashi, Tetsuya Kimura   +5 more
doaj   +1 more source

Use of a p64 MW Flow Diverter with Hydrophilic Polymer Coating (HPC) and Prasugrel Single Antiplatelet Therapy for the Treatment of Unruptured Anterior Circulation Aneurysms: Safety Data and Short-term Occlusion Rates

Cardiovascular and Interventional Radiology, 2022
To assess the safety and short-term occlusion rates in procedures using the p64 MW hydrophilic polymer-coated (HPC) flow diverter (FD) with prasugrel single antiplatelet therapy (SAPT) for the treatment of anterior circulation saccular aneurysms.
V. Hellstern, M. Aguilar Pérez, E. Henkes, E. Donauer, C. Wendl, H. Bäzner, O. Ganslandt, H. Henkes   +7 more
semanticscholar   +1 more source

Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial.

The Lancet, 2020
BACKGROUND Current guidelines recommend potent platelet inhibition with ticagrelor or prasugrel in patients after an acute coronary syndrome. However, data about optimal platelet inhibition in older patients are scarce. We aimed to investigate the safety
M. Gimbel, Khalid Qaderdan, L. Willemsen, R. Hermanides, T. Bergmeijer, E. de Vrey, T. Heestermans, Melvyn Tjon Joe Gin, R. Waalewijn, S. Hofma, F. D. den Hartog, W. Jukema, C. von Birgelen, M. Voskuil, J. Kelder, V. Deneer, J. Ten Berg   +16 more
semanticscholar   +1 more source

Cost analysis of dual antiplatelet therapy with prasugrel and ticagrelor in patients with acute coronary syndrome after percutaneous coronary intervention

Российский кардиологический журнал, 2020
Aim. To conduct a cost analysis of using novel inhibitors of P2Y 12 (prasugrel and ticagrelor) in patients with acute coronary syndrome (ACS) in the Russian healthcare system.Material and methods.
I. N. Dyakov, E. A. Ushkalova
doaj   +1 more source

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)

Journal of atherosclerosis and thrombosis, 2022
Aim: To examine the efficacy and safety of prasugrel vs clopidogrel in thrombotic stroke patients at risk of ischemic stroke. Methods: This multicenter, active-controlled, randomized, double-blind, double-dummy, parallel group study enrolled thrombotic ...
T. Kitazono, M. Kamouchi, Y. Matsumaru, M. Nakamura, K. Umemura, H. Matsuo, N. Koyama, J. Tsutsumi, K. Kimura   +8 more
semanticscholar   +1 more source

P2Y12 Inhibitors in Acute Coronary Syndromes: A Real-World, Community-Based Comparison of Ischemic and Bleeding Outcomes

Journal of Interventional Cardiology, 2023
Background. Randomized trials have shown superiority of the novel P2Y12 inhibitors over clopidogrel in patients with acute coronary syndrome (ACS), but clinical benefit in the community remains controversial.
Amit Sachdeva, Ratnabhushan Mutyala, Neha Mantri, Shiyun Zhu, Edward McNulty, Matthew Solomon   +5 more
doaj   +1 more source

Prasugrel Dose De-escalation Therapy After Complex Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: A Post Hoc Analysis From the HOST-REDUCE-POLYTECH-ACS Trial.

JAMA cardiology, 2022
Importance De-escalation of dual-antiplatelet therapy through dose reduction of prasugrel improved net adverse clinical events after acute coronary syndrome (ACS), mainly through the reduction of bleeding without an increase in ischemic outcomes. However,
D. Hwang, Young-Hyo Lim, Kyung-Woo Park, K. Chun, J. Han, Han-Mo Yang, Hyun-Jae Kang, B. Koo, Jeehoon Kang, Y. Cho, S. Hong, Sanghyun Kim, S. Jo, Y. H. Kim, Weon Kim, Sung Yun Lee, Young Dae Kim, S. Oh, Jung-Hee Lee, Hyo‐Soo Kim   +19 more
semanticscholar   +1 more source